MedicinefromThe Atlantic1 day agoThe Next Ozempic Is Already Being Sold UndergroundRetatrutide, nicknamed "GLP-3," produced Phase 3 results showing average 71-pound (29%) weight loss—substantially exceeding semaglutide—yet remains unapproved.